Charcot-Marie-Tooth disease (CMT) is diagnosed through a combination of physical examination, nerve conduction studies, and genetic testing. Because CMT is inherited and progresses slowly, the process often begins when a person notices gradual weakness in their feet or lower legs, or when a family member has already been diagnosed. The diagnostic path typically moves from clinical signs to electrical nerve testing to genetic confirmation, though not every step is needed in every case.
What Doctors Look for on Exam
The diagnosis of CMT starts with a clinical evaluation. A neurologist will take a detailed medical and family history, then look for a recognizable pattern of physical signs. The most common include high foot arches, curled toes (hammertoes), and weakness in the ankles and feet that makes it hard to lift the foot while walking. This ankle weakness, called foot drop, often causes a distinctive gait where a person lifts their knees higher than normal to avoid tripping.
Muscle wasting in the lower legs is another hallmark. Over time, the calves can shrink while the upper legs stay relatively normal, creating a shape sometimes compared to an upside-down champagne bottle. Reduced reflexes at the ankle and knee, along with numbness or tingling in the feet and hands, round out the typical picture. In some forms of CMT, a doctor can actually feel thickened nerves through the skin, particularly near the elbow. Children may first come to attention because of clumsiness, frequent tripping, or difficulty running compared to peers. Mild scoliosis or hip joint abnormalities can also be early clues in younger patients.
Nerve Conduction Studies and EMG
After the physical exam, the next step is usually a nerve conduction study, often paired with electromyography (EMG). These tests measure how fast and how strongly electrical signals travel through your nerves and into your muscles. They serve two purposes: confirming that a neuropathy exists, and helping determine which type of CMT you might have.
The speed at which signals travel through your nerves is the key measurement. In the most common form, CMT1, the protective coating around nerves (myelin) is damaged, which slows signal transmission significantly. Nerve conduction velocities in CMT1 patients typically fall around 20 m/s, well below the normal range of roughly 50 m/s or higher. In CMT2, the nerve fibers themselves are damaged rather than the coating, so conduction speed stays closer to normal while the strength of the signal drops. The X-linked form of CMT falls in between, with affected men showing speeds around 31 m/s and women around 45 m/s. These speed ranges help neurologists narrow down the subtype before genetic testing even begins.
EMG, which uses a thin needle electrode in the muscle, can show whether muscles are losing their nerve supply. This helps distinguish CMT from conditions that affect muscles directly rather than nerves.
Genetic Testing
Genetic confirmation is the most definitive step in diagnosing CMT. Current guidelines recommend a sequential approach: test for the most common cause first, then broaden the search if needed.
The single most frequent cause of CMT is a duplication of the PMP22 gene, which accounts for the majority of CMT1 cases. Testing for this duplication is fast and relatively inexpensive, so it’s usually done first. If that comes back negative, doctors typically move to next-generation sequencing panels that screen dozens of genes at once. About 90% of all genetically confirmed CMT cases trace back to just four genes: PMP22, GJB1, MFN2, and MPZ. The remaining confirmed cases involve mutations spread across a wide range of less common genes, including SH3TC2, GDAP1, and others.
The challenge is that CMT is extraordinarily genetically diverse. More than 130 genes and over 160 subtypes have been identified so far. Despite this, up to 40% of patients who clearly have CMT based on their symptoms and nerve studies never receive a confirmed genetic diagnosis with current testing technology. A negative genetic test does not rule out CMT. It simply means the specific mutation hasn’t been identified yet.
Ruling Out Other Conditions
Part of the diagnostic process involves making sure something else isn’t causing the neuropathy. Several treatable conditions can mimic CMT, and missing them would mean missing an opportunity for effective treatment. The list of look-alikes includes chronic inflammatory demyelinating polyneuropathy (CIDP), which is an immune-mediated condition that responds to treatment, as well as neuropathies caused by diabetes, thyroid disease, vitamin B12 deficiency, alcohol use, and certain infections.
Family history is one of the strongest tools for distinguishing CMT from acquired neuropathies. If multiple relatives across generations have similar symptoms, a hereditary cause is far more likely. The slow, symmetrical progression of CMT also looks different from many acquired neuropathies, which can develop more rapidly or affect one side more than the other. Blood tests for common metabolic and immune causes of neuropathy are often part of the initial workup to check for these alternatives.
When Nerve Biopsy Is Considered
Nerve biopsy, where a small piece of nerve tissue is surgically removed and examined under a microscope, was once a more routine part of CMT diagnosis. Today it plays a very limited role. With genetic testing and nerve conduction studies available, biopsy is rarely needed to confirm CMT specifically. It is still useful when doctors suspect conditions like vasculitis (blood vessel inflammation affecting nerves), nerve tumors, or amyloid deposits, but these are situations where CMT is being ruled out rather than confirmed. If your neurologist has already identified a clear clinical picture and nerve conduction pattern consistent with CMT, biopsy is unlikely to be recommended.
How the Diagnostic Timeline Varies
The age at which CMT is diagnosed varies widely. Many people with CMT1 show signs in childhood or adolescence, with parents noticing awkward gait, difficulty with sports, or shoes that never seem to fit right because of high arches. CMT2 tends to appear later, sometimes not until the 20s or 30s, because the nerve damage progresses more slowly and the early symptoms are subtler.
One common frustration is the time between first symptoms and an actual diagnosis. Because CMT is relatively rare and its early signs overlap with many other conditions, some people see multiple doctors over several years before getting an answer. Having a known family history speeds up the process considerably. If a relative has a confirmed genetic mutation, targeted testing for that specific mutation can provide a diagnosis quickly, sometimes from a single blood draw. For families without a prior diagnosis, the full workup from initial exam through genetic testing panels may take several months, depending on insurance approvals and lab turnaround times.